Barclays PLC Has $107,000 Position in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Barclays PLC increased its stake in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 320.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,472 shares of the company’s stock after buying an additional 30,095 shares during the quarter. Barclays PLC’s holdings in Akoya Biosciences were worth $107,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. State Street Corp grew its position in Akoya Biosciences by 4.2% during the third quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after buying an additional 18,361 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after purchasing an additional 144,903 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Akoya Biosciences by 16.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares in the last quarter. Finally, Regal Investment Advisors LLC boosted its holdings in shares of Akoya Biosciences by 64.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after purchasing an additional 7,340 shares in the last quarter. Institutional investors and hedge funds own 79.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AKYA. Canaccord Genuity Group reduced their target price on Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a report on Friday, November 15th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Finally, Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $7.00 to $5.00 in a research note on Friday, November 15th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.43.

Akoya Biosciences Stock Up 1.5 %

Shares of NASDAQ:AKYA opened at $2.66 on Thursday. The firm has a market cap of $131.84 million, a P/E ratio of -2.25 and a beta of 1.18. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. Akoya Biosciences, Inc. has a 12-month low of $1.88 and a 12-month high of $6.31. The business has a fifty day simple moving average of $2.48 and a 200 day simple moving average of $2.53.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.